As co‑founder and CEO of AstriVax Therapeutics, she played a pivotal role in securing €36 million in funding, successfully scaling the company from academic innovation to a clinical-stage biotech with a team of 20. AstriVax develops viral‑targeted immunotherapies for chronic viral infections through its proprietary Launch‑iT platform.

Hanne brings deep expertise in regulatory affairs, drug and vaccine development, and intellectual property, combined with a strong track record in building high‑performing teams and purpose‑driven company cultures.Committed to giving back, she actively shares her experience with the next generation and is a recurring guest lecturer at KU Leuven and Solvay Business School.